Decio L. Eizirik (WEL Research Institute - ULB) is the recipient of the prestigious George Eisenbarth Memorial Lecture that will be delivered at the 15th annual Network for Pancreatic Organ Donors with Diabetes (nPOD) meeting in Florida, USA.
Miikka Vikkula (WEL Research Institute - UCLouvain) is the recipient of the prestigious Earl P. Benditt Award which he will receive at the 2023 edition of the North American Vascular Biology Organization (NAVBO) meeting in Rhode Island, USA.
Alain Vanderplasschen (WEL Research Institute – ULiège) and his team demonstrated a key role for the Zalpha protein domain of Cyprinid herpesvirus 3 in the mechanism of viral infection in carp.
Sophie Lucas’ team (WEL Research Institute - UCLouvain) showed that the strategy of blocking GARP, a novel immuno-oncology target under clinical investigation for solid cancers, also has potential in "liquid" tumours.
Opening on 15 December 2022 of the first "WEL-T Investigator Programme" call.
⇒ The recording of the Dec 09 information webinar in English is available here.
The WEL Research Institute supports strategic research of excellence within its departments: WELBIO (life sciences) and WEL-T (engineering sciences, chemistry, physics) for an impact in health and sustainable transition.
La « Rentrée des Chercheuses et des Chercheurs WELBIO » fut l’occasion pour WELBIO de présenter sa stratégie et ses grands axes de développement, ainsi que quelques programmes de recherche dans différents domaines, à différents stades d’évolution.
David Vermijlen (WELBIO – ULB) et son équipe décrivent les mécanismes du développement des cellules T γδ du système immunitaire qui sont des cibles particulièrement attrayantes pour l'immunothérapie du cancer.
Decio Eizirik's team (WELBIO-ULB) demonstrates the dual role played by NLRC5 within beta cells in the early stages of the disease.
Vendredi 7 octobre prochain, de 12 à 14h
Aux Moulins de Beez (Namur)
➡ Infos et inscription ici
THERAtRAME SA, a new spin-off of the University of Liège and WELBIO, secures €4.5M seed financing to develop novel cancer medicines in the field of tRNA epitranscriptomics.
Alain Chariot (WELBIO – ULiège) and his team demonstrated the key role of ELP3-mediated tRNA modifications in the biology of immune cells.
